Slated to open within six months, the new pharmaceutical plant is currently under construction by Biopharma. The company already exports its products to dozens of countries and plans to further expand its footprint across Europe, the Middle East, and Latin America.
This was reported by Channel 24, according to Dengi.ua .
Biopharma Facility in Transcarpathia: Timeline and Production Portfolio
Biopharma is currently finalizing the first phase of what will be one of Europe’s largest plants for pharmaceutical and immunobiological production. According to the Prime Minister Yulia Svyrydenko, the enterprise is expected to become operational as early as September.
The new facility will enable a full, end-to-end blood plasma processing cycle within Ukraine—from raw material collection to the manufacture of finished medicinal products. Construction of the primary production building and raw material warehouse is complete, and the modern technological equipment necessary for the launch has been installed.
- Job Creation: The launch of the first stage will create approximately 150 new jobs, providing a significant boost to the local economy and labor market.
- Investment: The company's current investment in this phase totals €67 million, while the total cost of the first stage is estimated at €75 million.